World Health Organization Reviewed Medical Efficacy of CBD

Over the past five days, the World Health Organization’s (WHO) Expert Committee on Drug Dependence (ECDD) has been conducting its 39th meeting in Geneva, Switzerland.

The ECDD meeting, held from Nov. 6-10, offered an opportunity for committee members to deliberate about a number of different substances and whether these drugs deserved more or less scrutiny based on their potential for physical addiction and abuse. The WHO then makes recommendations based on the ECDD findings to countries around the world regarding which substances should be controlled or surveilled more closely than others.

Over the course of the 39th ECDD meeting, the committee reviewed critical new information and data concerning 16 different substances, including:

1. Ocfentanil
2. Furanyl fentanyl (Fu-F)
3. Acryloylfentanyl (Acrylfentanyl)
4. Carfentanil
5. 4-fluoroisobutyrfentanyl (4-FIBF, pFIBF)
6. Tetrahydrofuranylfentanyl (THF-F)
7. 4-fluoroamphetamine (4-FA)
8. AB-PINACA
9. AB-CHMINACA
10. 5F-PB-22
11. UR-144
12. 5F-ADB
13. Etizolam
14. Pregabalin
15. Tramadol
16. Cannabidiol (CBD)

The WHO prepares a pre-review report for each substance so the committee can fully prepare themselves.

The report on CBD states that the naturally…